Ligand Pharmaceuticals LGND Others — Gross carrying value
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's others — gross carrying value.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's others — gross carrying value?
- Ligand Pharmaceuticals (LGND) reported others — gross carrying value of $5.74M in Q1 2026.
- What does others — gross carrying value mean?
- This metric represents the total historical cost or initial book value of intangible assets and royalty rights held within the 'Others' business segment before accounting for any accumulated amortization or valuation allowances. It serves as a baseline measure of the capital invested in the underlying intellectual property and licensing agreements managed by this segment. Tracking this value helps investors understand the scale of the company's asset base dedicated to non-core or emerging pharmaceutical technologies.